A Phase 3, Open-label, Single-arm Study Evaluating the Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Who Are Intolerant or Refractory to Current Cytoreductive Treatment
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Platelet count
At least monthly, efficacy will not be determined until subjects have receive at least 3 months of treatment.
Monthly
Yes
Kanakura, Prof
Principal Investigator
Osaka University Hospital
Japan: Pharmaceuticals and Medical Devices Agency
SPD422-308
NCT01214915
November 2010
October 2012
Name | Location |
---|